Valuation: Glaukos Corporation

Market Cap 9.21B 8.05B 7.43B 6.83B 12.93B 886B 13.16B 88.66B 34.79B 433B 34.58B 33.82B 1,493B P/E 2026 *
-167x
P/E 2027 * 994x
Enterprise Value 8.96B 7.83B 7.23B 6.64B 12.59B 862B 12.8B 86.29B 33.86B 421B 33.65B 32.92B 1,453B EV / Sales 2026 *
14.2x
EV / Sales 2027 * 11.2x
Free-Float
96.33%
Yield 2026 *
-
Yield 2027 * -
1 day+2.88%
1 week+2.54%
Current month+12.22%
1 month+20.52%
3 months+29.62%
6 months+37.00%
Current year+38.91%
1 week 143.11
Extreme 143.11
157.71
1 month 125.43
Extreme 125.43
157.71
Current year 93.96
Extreme 93.96
157.71
1 year 73.16
Extreme 73.16
157.71
3 years 59.22
Extreme 59.22
163.71
5 years 33.33
Extreme 33.33
163.71
10 years 23.08
Extreme 23.075
163.71
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2001
Director of Finance/CFO 56 01/04/2022
President 50 01/04/2022
Director TitleAgeSince
Chairman 65 31/12/2021
Director/Board Member 71 01/07/2014
Director/Board Member 57 01/07/2014
Date Insider Type Main position Quantity % Market Cap.
07-09Fiscal year

Chief Financial Officer

30,000 0.0523%
07-06Fiscal year

Chief Financial Officer

30,000 0.0523%
07-01Sell

Executive/Senior Manager

-716 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+2.88%+2.54%+59.62%+98.31% 9.21B
+1.73%-3.18%-18.98%+4.63% 121B
-1.30%+0.62%+3.74%-3.76% 13.07B
+9.11%+8.59%-45.41%-70.81% 4.2B
+3.08%+11.31%+15.91%+54.14% 2.91B
+3.86%-2.49%-15.39%-27.03% 1.73B
+1.54%+4.12%-5.20%-19.99% 1.67B
+3.81%+8.29%-17.18%-60.78% 1.47B
+2.75%+2.43%-60.55%-84.51% 1.46B
Average +3.05%+3.56%-9.27%-12.20% 17.45B
Weighted average by Cap. +1.82%-1.66%-12.73%+6.28%

Financials

2026 *2027 *
Net sales 630M 551M 508M 467M 885M 60.6B 900M 6.06B 2.38B 29.62B 2.36B 2.31B 102B 789M 690M 637M 585M 1.11B 75.96B 1.13B 7.6B 2.98B 37.13B 2.96B 2.9B 128B
Net income -56.38M -49.29M -45.47M -41.8M -79.2M -5.43B -80.56M -543M -213M -2.65B -212M -207M -9.14B 9.02M 7.89M 7.27M 6.69M 12.67M 868M 12.89M 86.84M 34.08M 424M 33.87M 33.13M 1.46B
Net Debt -246M -215M -199M -182M -346M -23.68B -352M -2.37B -930M -11.58B -924M -904M -39.9B -402M -351M -324M -298M -565M -38.67B -574M -3.87B -1.52B -18.9B -1.51B -1.48B -65.15B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
15/07/26 $156.84 +2.88% 630,560
14/07/26 $152.45 -0.18% 517,354
13/07/26 $152.72 0.00% 442,231
10/07/26 $152.72 -1.52% 672,327
09/07/26 $155.07 +1.38% 781,020
Trader
Investor
-
Global
-
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
156.84USD
Average target price
162.92USD
Spread / Average Target
+3.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock